Clinical Trial Search

Primary: Percent of Patients Achieving American College of Rheumatology Score of at Least 20% (ACR20) Response Criteria on Secukinumab 300 mg and 150 mg vs. Placebo at Week 16…

Primary: Rosenberg Self-Esteem Scale — 13.9; 24.6; 13.5; 23.3 units on a scale

Primary: Treatment Emergent Adverse Event (TEAE) Occurrence — 0 Participants

Primary: Width of Stretch Marks — 0.199; 0.146; 0.088; 0.077 centimeters

Primary: Sustained Virological Response (SVR) at Week 12 — 116; 66 Participants

Primary: Percent Change From Baseline in Spine Bone Mineral Density by Dual X-ray Absorptiometry (DXA) — 7.69; 12.70 percent change in BMD

Primary: Number of Participants With Satisfactory Clinical Response at Week 24 — 45; 23; 66; 90 Participants — p=0.0007

Primary: Number of Enrolled Participants That Completed All 24 Week Procedures — 8; 13 Participants

Primary: Spastic Hypertonia as Measured by the Ashworth Scale — 2.4; 2.33; 2.36 score on a scale

Primary: Change in Peak Oxygen Uptake From Baseline Peak Oxygen Uptake — -2.01; -1.01 ml/kg/min

Primary: Change in Median Dyspareunia Pain Scores After 4 Weeks Using Study Drug — -1.5; -3 score on a scale — p=0.08

Primary: Number of Patients Who Achieved Treatment Success — 4; 0 Participants

Primary: Number of Days Until Alleviation of Flu Symptoms Post Treatment — 5.3; 4.9 days

Primary: Corrected Glucose Disposal Rate (cGDR) Measured as Change in Rate of Disposal (Delta RD) Basal vs High Insulin After 5 Weeks of Treatment — 8.523; 9.592…

Primary: Change in Lumbar Spine BMD From Baseline to 6 Months After the Zoledronic Acid Infusion. — -2.1; -4.3; -3.0 percentage change